Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 16/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.55 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468158 | 0.90 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1TRAP1HPGDALDH1A1 | |
| SCHEMBL5458097 | 0.86 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1TRAP1HPGDALDH1A1 | |
| SCHEMBL14582379 | 0.86 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1TRAP1HPGDALDH1A1 | |
| SCHEMBL14582381 | 0.85 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1TRAP1HPGDALDH1A1 | |
| SCHEMBL14582380 | 0.83 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1TRAP1HPGD | |
| SCHEMBL4620866 | 0.83 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1TRAP1HPGDALDH1A1 | |
| SCHEMBL5471332 | 0.83 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1TRAP1HPGDALDH1A1 | |
| SCHEMBL1779006 | 0.82 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1TRAP1HPGDALDH1A1 | |
| SCHEMBL5465114 | 0.82 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1TRAP1HPGDALDH1A1 | |
| SCHEMBL4618394 | 0.82 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1TRAP1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | TK1, TK2, SLC1A5 | HSP90AA1 3373/4885HSP90AB1 3036/4885TRAP1 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.